SCHEDULE 13D 2-24-17

Company

Viridian Therapeutics, Inc.\DE

Filed

February 24, 2017

Accession Number

0001596770-17-000004

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →